|
London, UK, and Cambridge, MA, 15 August 2008 - Antisoma plc today announced survival data from its phase II study of ASA404 in hormone-refractory prostate cancer, in which patients were randomised to receive ...
|
|
A combination of two chemotherapy regimens may be a viable alternative to current treatments for non-small cell lung cancer.
|
|
Main Category: Lung Cancer Also Included In: Medical Devices / Diagnostics ; Respiratory / Asthma ; Cancer / Oncology Article Date: 14 Aug 2008 - 2:00 PDT Accuray Incorporated , a global leader in the field of ...
|
|
In a phase II multicenter study of 56 patients with an advanced form of this common lung cancer, endpoints including response rate, progression-free survival, and overall survival from use of S-1 and irinotecan ...
|
|
... Prodrug (HAP) that specifically targets tumor hypoxia. "Targeting tumor hypoxia is an exciting area of cancer research, and may offer great promise to patients with a wide variety of cancers," said Dr. Jeffrey Infante, M.D., Sarah Cannon Research ...
|
|
Geron Corporation announced the enrollment of the first patient in a clinical trial of its telomerase inhibitor drug, GRN163L, in locally recurrent or metastatic breast cancer.
|
|
... focus on subjects such as Alzheimer's Disease, Benign Prostatic Hyperplasia, ADHD, Parkinson's Disease, Migraine, Non-Small Cell Lung Cancer and Hypertension. "Today's physicians are faced with an overwhelming challenge in keeping up-to-date with ...
|
|
... and a significant Cyclacel presence at major oncology conferences during the quarter, have underscored our expertise in cell cycle science and our ongoing commitment to creating treatments for multiple cancers in which significant unmet need still ...
|